Compugen (CGEN)
(Delayed Data from NSDQ)
$1.74 USD
-0.02 (-1.14%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.73 -0.01 (-0.57%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CGEN 1.74 -0.02(-1.14%)
Will CGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CGEN
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Alterity (ATHE) Up on Interim Data From Advance MSA Study
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Other News for CGEN
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
Compugen to Present at Single Cell Genomics 2024 Conference
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen: Strong Buy on Promising Trials, Strategic Alliances, and Solid Financials